

## Pharmacy and Therapeutics (P&T) Committee Meeting

Tuesday, August 21<sup>st</sup> 2018, 6:30 p.m. to 8:00 p.m.

### Agenda

<u>Topic:</u>	<u>Presenter:</u>
<p>1. <b>Welcome</b></p> <ul style="list-style-type: none"> <li>• Call to Order</li> <li>• Roll Call</li> </ul>	<p>Carl Antolick III, Chair</p>
<p>2. <b>Conflict of Interest Statement</b></p>	<p>Carl Antolick III, Chair</p>
<p>3. <b>Old Business</b></p> <ul style="list-style-type: none"> <li>• Formulary Development and Management at CVS Caremark</li> <li>• Minutes from May 22, 2018 Meeting*</li> <li>• Recent Plan Formulary Decisions</li> </ul>	<p>Carl Antolick III, Chair</p>
<p>4. <b>Formulary Updates*</b></p> <ul style="list-style-type: none"> <li>• Formulary Drug Exclusions</li> <li>• Tier Changes               <ul style="list-style-type: none"> <li>○ Uptier</li> <li>○ Downtier</li> </ul> </li> <li>• Formulary Additions</li> </ul>	<p>Carl Antolick III, Chair</p> <p>Heather Renee Jarnigan, CVS</p> <p>Heather Renee Jarnigan, CVS</p>
<p>5. <b>Utilization Management Policy Review*</b></p> <ul style="list-style-type: none"> <li>• New Policies Under Consideration               <ul style="list-style-type: none"> <li>○ Nuedexta® Initial Prior Authorization</li> <li>○ Topical NSAIDs Initial Prior Authorization with Quantity Limits</li> <li>○ Topical Vitamin D Analogs Initial Prior Authorization</li> <li>○ Chenodal® Initial Prior Authorization</li> <li>○ Naprelan® Initial Prior Authorization</li> <li>○ Thiola® Initial Prior Authorization</li> </ul> </li> </ul>	<p>Carl Antolick III, Chair</p> <p>Stephanie Morrison, CVS</p>
<p>6. <b>Adjourn</b></p> <ul style="list-style-type: none"> <li>• Next Meeting: <i>Tuesday October 23, 2018 from 6:30 to 8:00 PM via webinar</i></li> </ul>	<p>Carl Antolick III, Chair</p>